TG Therapeutics (TGTX) is trading higher as investors react to a key development milestone for BRIUMVI: the company completed enrollment in its Phase 3 trial evaluating a subcutaneous formulation in relapsing forms of multiple sclerosis. The milestone supports confidence that TG can expand BRIUMVI beyond the current IV-only regimen and potentially unlock a more convenient, self-administered option for patients. (globenewswire.com)

The Phase 3 study compares subcutaneous BRIUMVI dosing every 8 weeks or every 12 weeks versus the currently approved IV dosing schedule, with a primary goal of showing non-inferior drug exposure versus IV at week 24. If successful, the subcutaneous program could broaden use by enabling more flexible administration, including a potential at-home option—an important differentiator in a competitive anti-CD20 multiple sclerosis landscape. (globenewswire.com)

TG expects to report top-line results around year-end 2026 or in the first quarter of 2027, putting the next major data readout squarely on the medium-term horizon rather than the near term. Investors will also watch for additional BRIUMVI clinical and commercial updates around the upcoming neurology conference calendar, where the company has indicated scheduled scientific presentations in late April 2026. (globenewswire.com)